Information Provided By:
Fly News Breaks for February 5, 2020
Feb 5, 2020 | 06:25 EDT
JMP Securities analyst David Turkaly initiated coverage of iCAD with an Outperform rating and $15 price target. The analyst is positive on the company's platform focus of improving detection of early stage cancers, stating its products offer "meaningful benefits to patients, customers, and healthcare providers alike". Turkaly also cites "notable progress" made by iCAD in 2019 under CEO Mike Klein, with the company posting a double-digit, top-line growth driven by the successful commercial launch of its ProFound AI detection product.
News For ICAD From the Last 2 Days
There are no results for your query ICAD